Boehringer Settlement Jumps The Queue For Biosimilar Adalimumab

15 May 2019

Boehringer Ingelheim has settled litigation with AbbVie over Humira by striking a deal that allows it to launch its biosimilar adalimumab in the US from the start of July 2023.

Balloons — Boehringer Ingelheim has landed in third place with its entry date of 1 July 2023 • Source: Shutterstock

Boehringer Ingelheim will be able to launch its biosimilar rival to AbbVie’s Humira (adalimumab) in the US from 1 July 2023 after settling patent litigation with the originator, putting it ahead of many of its competitors.

The agreement marks the end of all Humira-related patent litigation in the US, after a host of other biosimilars sponsors...